Literature DB >> 25109614

Fostering adherence to injectable disease-modifying therapies in multiple sclerosis.

Alessandra Lugaresi1, Maria Rosa Rottoli, Francesco Patti.   

Abstract

Multiple sclerosis requires long-term management, often with disease-modifying therapies. Poor medication adherence, especially to injectables, can increase relapse and hospitalisation rates and consume healthcare resources. We discuss adherence definitions and terminology and its prevalence in multiple sclerosis (MS). Typical causes of poor adherence in patients with MS include: insufficient efficacy or tolerability, concurrent disorders, and consequences of MS (e.g., forgetfulness, depression, fatigue and poor motor skills). Ways to improve adherence rates are reviewed, focusing on interdisciplinary healthcare teams, good communication between healthcare workers and patients (and their families), ongoing support and digital tools to promote adherence. We consider open communication and continuing education to be key, and that MS nurses have a pivotal role in ensuring patients' adherence to MS medicines.

Entities:  

Keywords:  communication; concordance; disease-modifying therapy; education; healthcare; multiple sclerosis; nurse

Mesh:

Substances:

Year:  2014        PMID: 25109614     DOI: 10.1586/14737175.2014.945523

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  18 in total

1.  Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience.

Authors:  E D'Amico; A Zanghì; M Sciandra; G Borriello; G Callari; A Gallo; G Salemi; S Cottone; M Buccafusca; P Valentino; R B Bossio; L M E Grimaldi; C Pozzilli; G Tedeschi; M Zappia; F Patti
Journal:  J Neurol       Date:  2018-12-04       Impact factor: 4.849

2.  Persistence to oral disease-modifying therapies in multiple sclerosis patients.

Authors:  Simona Lattanzi; Maura Danni; Ruja Taffi; Raffaella Cerqua; Giulia Carlini; Alessandra Pulcini; Leandro Provinciali; Mauro Silvestrini
Journal:  J Neurol       Date:  2017-08-22       Impact factor: 4.849

Review 3.  Treatment strategies for multiple sclerosis: When to start, when to change, when to stop?

Authors:  Alberto Gajofatto; Maria Donata Benedetti
Journal:  World J Clin Cases       Date:  2015-07-16       Impact factor: 1.337

4.  From Medical Prescription to Patient Compliance: A Qualitative Insight into the Neurologist-Patient Relationship in Multiple Sclerosis.

Authors:  Vincent Schlegel; Emmanuelle Leray
Journal:  Int J MS Care       Date:  2018 Nov-Dec

5.  Patient satisfaction with the BETACONNECT™ autoinjector for interferon beta-1b.

Authors:  Ivonne Weller; Anna Saake; Thomas Schreiner; Julika Vogelreuter; Nicolas Petroff
Journal:  Patient Prefer Adherence       Date:  2015-07-07       Impact factor: 2.711

6.  Survey of US Patients with Multiple Sclerosis: Comparison of the New Electronic Interferon Beta-1b Autoinjector (BETACONNECT™) With Mechanical Autoinjectors.

Authors:  Donald A Barone; Barry A Singer; Lubo Merkov; Mark Rametta; Gustavo Suarez
Journal:  Neurol Ther       Date:  2016-06-08

7.  Adherence, satisfaction and functional health status among patients with multiple sclerosis using the BETACONNECT® autoinjector: a prospective observational cohort study.

Authors:  Ingo Kleiter; Michael Lang; Judith Jeske; Christiane Norenberg; Barbara Stollfuß; Markus Schürks
Journal:  BMC Neurol       Date:  2017-09-06       Impact factor: 2.474

8.  Patient Satisfaction with the New Interferon Beta-1b Autoinjector (BETACONNECT™).

Authors:  Tjalf Ziemssen; Lauren Sylvester; Mark Rametta; Amy Perrin Ross
Journal:  Neurol Ther       Date:  2015-10-27

9.  Treatment adherence in multiple sclerosis: a survey of Belgian neurologists.

Authors:  Danny Decoo; Mathieu Vokaer
Journal:  Patient Prefer Adherence       Date:  2015-11-19       Impact factor: 2.711

Review 10.  Interferon-Related Depression: A Primer on Mechanisms, Treatment, and Prevention of a Common Clinical Problem.

Authors:  Ekta Franscina Pinto; Chittaranjan Andrade
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.